

# Youn H Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8467341/publications.pdf>

Version: 2024-02-01

84  
papers

7,229  
citations

182225  
30  
h-index

78623  
77  
g-index

86  
all docs

86  
docs citations

86  
times ranked

5861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
2	Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. <i>Blood</i> , 2022, 139, 3732-3736.	0.6	19
3	Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 561-570.	3.3	2
4	Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders. <i>Journal of Dermatological Treatment</i> , 2021, 32, 101-103.	1.1	1
5	Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 119-124.e4.	0.2	11
6	Pembrolizumab in mycosis fungoides with PD-L1 structural variants. <i>Blood Advances</i> , 2021, 5, 771-774.	2.5	21
7	Two Cases of Mycosis Fungoides With <i>PCM1-JAK2</i> Fusion. <i>JCO Precision Oncology</i> , 2021, 5, 646-652.	1.5	5
8	Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. <i>Cancer Investigation</i> , 2021, , 1-11.	0.6	0
9	Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. <i>Frontiers in Immunology</i> , 2021, 12, 687673.	2.2	59
10	Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and SÅ©zary Syndrome. <i>Advances in Radiation Oncology</i> , 2021, 6, 100629.	0.6	12
11	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
12	Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or SÅ©zary Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 700.	2.0	36
13	Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 18, 12-15.	0.6	3
14	Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	4
15	Cutaneous T cell lymphoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 61.	18.1	70
16	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46
17	Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. <i>European Journal of Cancer</i> , 2021, 156, S48-S49.	1.3	6
18	Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 622-622.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma. <i>Blood</i> , 2021, 138, 1325-1325.	0.6	1
20	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. <i>Nature Communications</i> , 2021, 12, 6726.	5.8	101
21	What factors guide treatment selection in mycosis fungoides and Sezary syndrome?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 303-312.	0.9	5
22	Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S�zary Syndrome: A Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 20-28.	0.8	160
23	Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. <i>Diagnostic Pathology</i> , 2020, 15, 122.	0.9	7
24	Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. <i>Cancers</i> , 2020, 12, 2311.	1.7	38
25	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21
26	A Long-Term Study of Persistent S�zary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. <i>American Journal of Dermatopathology</i> , 2020, 42, 389-396.	0.3	0
27	Histopathologic Characterization of Mogamulizumab-associated Rash. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1666-1676.	2.1	23
28	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	0.6	3
29	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-43.	0.6	5
30	Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 970-976.	0.6	14
31	Angiodestructive lymphomatoid papulosis lasting more than 45�years. <i>JAAD Case Reports</i> , 2019, 5, 767-769.	0.4	4
32	Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. <i>Practical Radiation Oncology</i> , 2019, 9, 220-225.	1.1	4
33	Utility of CD30, Ki�67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 33-43.	0.7	10
34	Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. <i>Neoplasia</i> , 2019, 21, 82-92.	2.3	40
35	Measurement of Quality of Life in Patients with Mycosis Fungoides/S�zary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. <i>Journal of Medical Internet Research</i> , 2019, 21, e11302.	2.1	13
36	Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard <sc>PDT</sc>, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T�cell Lymphoma. <i>Photochemistry and Photobiology</i> , 2018, 94, 1058-1065.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Transcript-indexed ATAC-seq for precision immune profiling. <i>Nature Medicine</i> , 2018, 24, 580-590.	15.2	124
38	Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1204-1206.	0.3	19
39	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	0.6	28
40	Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. <i>JAMA Dermatology</i> , 2018, 154, 728.	2.0	23
41	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1192-1204.	5.1	398
42	Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. <i>Modern Pathology</i> , 2017, 30, 761-772.	2.9	74
43	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 3552-3556.	3.2	20
44	Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. <i>Journal of Neuro-Oncology</i> , 2017, 132, 439-446.	1.4	33
45	Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. <i>Cancer Cell</i> , 2017, 32, 27-41.e4.	7.7	136
46	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , 2017, 390, 555-566.	6.3	444
47	Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. <i>JAAD Case Reports</i> , 2017, 3, 310-315.	0.4	14
48	An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone. <i>JAAD Case Reports</i> , 2017, 3, 276-279.	0.4	3
49	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
50	Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Multicenter Phase 2 Study. <i>Blood</i> , 2016, 128, 181-181.	0.6	56
51	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. <i>Blood</i> , 2016, 128, 182-182.	0.6	12
52	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. <i>Blood</i> , 2016, 128, 1826-1826.	0.6	6
53	A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). <i>Blood</i> , 2016, 128, 4165-4165.	0.6	5
54	Subcutaneous panniculitis-like T-cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2025-2028.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 286-292.	0.6	156
56	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÅ@zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. <i>Journal of Clinical Oncology</i> , 2015, 33, 3750-3758.	0.8	235
57	Genomic analysis of mycosis fungoides and SÅ@zary syndrome identifies recurrent alterations in TNFR2. <i>Nature Genetics</i> , 2015, 47, 1056-1060.	9.4	242
58	Lymph node involvement by mycosis fungoides and SÅ@zary syndrome mimicking angioimmunoblastic T-cell lymphoma. <i>Human Pathology</i> , 2015, 46, 1382-1389.	1.1	5
59	Individuality and Variation of Personal Regulomes in Primary Human T Cells. <i>Cell Systems</i> , 2015, 1, 51-61.	2.9	128
60	Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and SÅ@zary Syndrome. <i>Clinical Cancer Research</i> , 2015, 21, 274-285.	3.2	125
61	Outcomes After Diagnosis of Mycosis Fungoides and SÅ@zary Syndrome Before 30 Years of Age. <i>JAMA Dermatology</i> , 2014, 150, 709.	2.0	26
62	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and SÅ@zary Syndrome (SS). <i>Blood</i> , 2014, 124, 2544-2544.	0.6	15
63	Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. <i>Blood</i> , 2014, 124, 3092-3092.	0.6	13
64	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression. <i>Blood</i> , 2014, 124, 804-804.	0.6	3
65	TG1042 (Adenovirus-interferon-Î³) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e83670.	1.1	28
66	Use of High-Throughput Sequencing (HTS) of TCRÅ@ to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. <i>Blood</i> , 2014, 124, 2473-2473.	0.6	0
67	In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. <i>Blood</i> , 2012, 119, 355-363.	0.6	202
68	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
69	Clinical End Points and Response Criteria in Mycosis Fungoides and SÅ@zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
70	Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome. <i>Blood</i> , 2011, 118, 3114-3114.	0.6	0
71	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 975-983.	0.6	90
72	Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.. <i>Blood</i> , 2010, 116, 2800-2800.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients. <i>Blood</i> , 2010, 116, 962-962.	0.6	18
74	Increased Risk of Second Malignancies In Young Patients with Mycosis Fungoides Diagnosed Before 30 Years of Age: A Population-Based Study. <i>Blood</i> , 2010, 116, 1994-1994.	0.6	0
75	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S��zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 479-484.	0.6	452
76	Revisions to the staging and classification of mycosis fungoides and S��zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
77	Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.. <i>Blood</i> , 2006, 108, 2467-2467.	0.6	12
78	Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.. <i>Blood</i> , 2006, 108, 2716-2716.	0.6	3
79	Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4+ Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.. <i>Blood</i> , 2006, 108, 2731-2731.	0.6	5
80	Marked Improvement in Staging Accuracy in Mycosis Fungoides/S��zary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).. <i>Blood</i> , 2004, 104, 3127-3127.	0.6	0
81	Management with topical nitrogen mustard in mycosis fungoides. <i>Dermatologic Therapy</i> , 2003, 16, 288-298.	0.8	44
82	Long-term Outcome of 525 Patients With Mycosis Fungoides and S��zary Syndrome. <i>Archives of Dermatology</i> , 2003, 139, 857-66.	1.7	570
83	Topical Nitrogen Mustard in the Management of Mycosis Fungoides. <i>Archives of Dermatology</i> , 2003, 139, 165-73.	1.7	171
84	Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course. <i>Journal of Clinical Oncology</i> , 2001, 19, 2179-2188.	0.8	153